National Comprehensive Cancer Network

About NCCN

NCCN Hosts Its Third Annual Global Corporate Council Meeting

Caitlin Donnelly, Business Insights Specialist, NCCN

The third annual National Comprehensive Cancer Network® (NCCN®) Global Corporate Council Meeting took place Thursday, March 23rd in conjunction with NCCN’s 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™.

In order to forward its mission to improve quality, effectiveness, and efficiency of cancer care so patients can live better lives, NCCN works with various stakeholders in health care, including industry. The NCCN Global Corporate Council is an important resource for the development and expansion of NCCN programs and resources around the world. Created in 2015, the Council is a membership opportunity for industry that serves to build relationships and facilitate collaboration while recognizing NCCN's necessary autonomy in all decision-making regarding the conclusions, recommendations and outcomes of NCCN programs and Resources. Since inception, the program has grown rapidly and now has 20 members, eight of which are new to the Council in 2017.

The 2017 meeting commenced as Robert W. Carlson, MD, Chief Executive Officer, NCCN, provided an overview of NCCN’s Global Program, outlining 2016 accomplishments and specific goals for the next two years. Dr. Carlson also shared details on the NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) including the reasoning and process of the creation of the NCCN Framework™.

Meg O’Brien, PhD, Director, Global Cancer Treatment, American Cancer Society (ACS), and Jeff Grosz, Director of Cancer, Clinton Health Access Initiative (CHAI), presented on the organizations’ efforts in Sub-Saharan Africa. They talked about the present state and cost of oncology care, and the collaborative effort between ACS, CHAI, IBM, and NCCN on a chemotherapy-forecasting tool called ChemoQuant. This tool allows countries to predict more accurately the amount of specific chemotherapy agents required to buy efficiently preventing future shortages. NCCN Framework™, as well as the NCCN Chemotherapy Order Templates (NCCN Templates®), were utilized as a reference for the ChemoQuant’s development.  

Benjamin O. Anderson, MD, Director, Breast Health Global Initiative, Fred Hutchinson Research Center/Seattle Cancer Care Alliance, and Claire Goodliffe, Global Oncology Director, GE Healthcare, presented the third segment, titled, “The One Stop Clinic for Breast Health”. First, Dr. Anderson discussed the state of Breast Cancer care in low- and middle-income countries, and the efforts of the Breast Health Global Initiative through their campaign, “Breast Cancer Initiative 2.5”. Ms. Goodliffe followed, speaking specifically to GE Healthcare’s endeavors to address the disparity problem. Their solution was a collaborative effort with Gustave Roussy Cancer Campus, France to create the One-Stop Clinic, an organizational means to shorten the length of time between initial diagnosis and treatment. 

Finally, NCCN announced a new program for its global audience: NCCN Global Academy for Excellence & Leadership in Oncology™: School of Pharmaceutical & Biotech Business will take place on Friday, October 6, 2017, in San Francisco, CA, in conjunction with the NCCN 12th Annual Congress: Hematologic Malignancies™. NCCN Academy provides an opportunity for industry to learn and interact with relevant stakeholders about emerging issues and best practices in the oncology space. This interactive program, in its ninth year, has proven to be an excellent educational opportunity, and is now expanding to cover the global environment. The inaugural curriculum for the NCCN Global Academy includes insights into the regional adaptation process of the NCCN Guidelines and best practices in global patient advocacy. The agenda is available to be viewed here.

The global influence and demand for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) is ever increasing. Today, nearly half of the more than 800,000 registered users of the NCCN Guidelines® on report that they live outside the United States. In order to help clinicians and patients with cancer outside the United States, NCCN strives to identify programming and execute on opportunities that have global impact. The rapid expansion of the NCCN Global Program is a reflection of this effort. Last year, NCCN translated 31 NCCN Guidelines into seven languages. Indeed more than 100 translated NCCN Guidelines are currently available on Moreover, NCCN is actively processing 16 regional adaptations, and the NCCN Framework™, which guides evidence-based adaptation to available clinical treatment resources, is available for 11 tumor types. The goal of the NCCN Framework™ is to define appropriate treatment pathways based on available resources—Basic, Core, Enhanced, and NCCN Guidelines®—and deliver a tool for health care providers to identify treatment options that will provide the best possible outcomes given specific resource constraints.

For more information about the NCCN Global Program, please contact Jorge Bacigalupo at

For more information about the NCCN Global Corporate Council and its membership opportunities, please contact Caitlin Donnelly at